Expression of Foxp3, CD25 and IL-2 in the B16F10 cancer cell line and melanoma is correlated with tumor growth in mice
- Authors:
- D. F. Miranda-Hernández
- M. A. Franco-Molina
- E. Mendoza-Gamboa
- P. Zapata-Benavides
- C. A. Sierra-Rivera
- E. E. Coronado-Cerda
- A. G. Rosas-Taraco
- R. S. Taméz-Guerra
- C. Rodríguez-Padilla
View Affiliations
Affiliations: Department of Immunology and Virology, Faculty of Biological Sciences, University Autonoma of Nuevo León (UANL), San Nicolás de los Garza, Nuevo León 66450, Mexico, Department of Immunology, Faculty of Medicine, University Autónoma of Nuevo León (UANL), Monterrey, Nuevo León 64460, Mexico
- Published online on: August 13, 2013 https://doi.org/10.3892/ol.2013.1526
-
Pages:
1195-1200
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The forkhead box P3 (Foxp3) transcription factor is one of the most studied markers used to identify CD4+CD25+ regulatory T cells (Tregs), and has been identified as a key regulator in the development and function of Tregs. Foxp3 expression has been reported in a variety of solid human tumors, including melanoma. The aims of the present study were to analyze Foxp3 expression in B16F10 melanoma cells in vitro, to determine whether this expression was affected during tumor growth in a murine melanoma model and to correlate Foxp3 expression with CD25 expression, interleukin (IL)-2 production and tumor weight. Foxp3 expression was analyzed with quantitative (q)PCR, flow cytometry and confocal microscopy. CD25 expression was analyzed by flow cytometry, and cytokine production was measured by ELISA [IL-2, interferon (IFN)-γ, transforming growth factor (TGF)-β and IL-10] and flow cytometry (IL-2, IFN-γ, IL-4 and IL-5). Foxp3 and CD25 expression was detected in the B16F10 cells in culture and in the intratumoral B16F10 cells. An increase in Foxp3 and CD25 expression was observed in a time-dependent manner during tumor growth at 7, 14 and 21 days. The production of the IL-2, IL-10, IFN-γ and TGF-β cytokines was observed in the B16F10 cells and also detected in the tumoral microenvironment during tumor growth (7, 14 and 21 days). An increase in IL-2 and IL-10 production was observed, whereas IFN-γ production decreased in a time-dependent manner. The production of tumor necrosis factor (TNF)-α was not observed in culture, but was detected during tumor growth, whereas the production of IL-4 and IL-5 was not detected. These data showed a positive correlation between the expression of Foxp3, CD25 and IL-2 and tumor weight in murine melanoma. From these data, it may be suggested that Foxp3 participates in melanoma growth, the modulation of the IL-2, IFN-γ and TNF-α cytokines and CD25 expression, and that it also plays a possible role in immunosuppression.
View References
|
1
|
Roncador G, Garcia JF, Garcia JF, Maestre
L, Lucas E, Menarguez J, Ohshima K, Nakamura S, Banham AH and Piris
MA: Foxp3, a selective marker for a subset of adult T-cell
leukemia/lymphoma. Leukemia. 19:2247–2253. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lu H: FOXP3 expression and prognosis: role
of both the tumor and T cells. J Clin Oncol. 27:1735–1736. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
von Boehmer H: Mechanisms of suppression
by suppressor T cells. Nat Immunol. 6:338–344. 2005.PubMed/NCBI
|
|
4
|
Niu J, Jiang C, Li C, Liu L, Li K, Jian Z
and Gao T: Foxp3 expression in melanoma cells as a possible
mechanism of resistance to immune destruction. Cancer Immunol
Immunother. 60:1109–1118. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Karanikas V, Speletas M, Zamanakou M,
Kalala F, Loules G, Kerenidi T, Barda AK, Gourgoulianis KI and
Germenis AE: Foxp3 expression in human cancer cells. J Transl Med.
6:192008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Merlo A, Casalini P, Carcangiu ML,
Malventano C, Triulzi T, Ménard S, Tagliabue E and Balsari A: FOXP3
expression and overall survival in breast cancer. J Clin Oncol.
27:1746–1752. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chin L, Garraway LA and Fisher DE:
Malignant melanoma: genetics and therapeutics in the genomic era.
Genes Dev. 20:2149–2182. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hinz S, Pagerols-Raluy L, Oberg HH,
Ammerpohl O, Grüssel S, Sipos B, Grützmann R, Pilarsky C,
Ungefroren H, Saeger HD, Klöppel G, Kabelitz D and Kalthoff H:
Foxp3 expression in pancreatic carcinoma cells as a novel mechanism
of immune evasion in cancer. Cancer Res. 67:8344–8350. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ebert LM, Tan BS, Browning J, Svobodova S,
Russell SE, Kirkpatrick N, Gedye C, Moss D, Ng SP, MacGregor D,
Davis ID, Cebon J and Chen W: The regulatory T cell-associated
transcription factor FoxP3 is expressed by tumor cells. Cancer Res.
68:3001–3009. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Monti P, Marchesi F, Reni M, Mercalli A,
Sordi V, Zerbi A, Balzano G, Di Carlo V, Allavena P and Piemonti L:
A comprehensive in vitro characterization of pancreatic ductal
carcinoma cell line biological behavior and its correlation with
the structural and genetic profile. Virchows Arch. 445:236–247.
2004. View Article : Google Scholar : PubMed/NCBI
|
